Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.49) per share which met the analyst consensus estimate. This is a 96 percent decrease over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $7.22 million which missed the analyst consensus estimate of $7.30 million by 1.04 percent. This is a 73.27 percent decrease over sales of $27.03 million the same period last year.
Mizuho Maintains Neutral on Fortinet, Raises Price Target to $310
Mizuho analyst Gregg Moskowitz maintains Fortinet (NASDAQ:FTNT) with a Neutral and raises the price target from $290 to $310.
